Geneva, Aug. 29 -- International Clinical Trials Registry received information related to the study (NCT07111832) titled 'A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer' on Aug. 1.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Condition:
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
Intervention:
Drug: SHR-A1811 for Injection
Drug: SHR-1316 Injection
Drug: Toripalimab Injection
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 2025
Target...